HighTide Therapeutics, Inc. (SEHK: 2511)
Health Care · Biotechnology · CN
HK$3.43
-2.14% today · -1.3% 1Y
HighTide Therapeutics, Inc. (SEHK: 2511) operates in the Biotechnology industry within the Health Care sector. The company is valued at $249.35M and employs 51 people.
Over the last twelve months the share price has lost 1.3%, trading between 1.80 and 4.72.
Tweenvest scores HighTide Therapeutics, Inc. across four factors: quality 36/100, value 88/100. Its strongest factor is value.
2511 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $249.35M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.53
- Dividend yield
- —
- Beta (5Y)
- -0.32
- 52-week high
- HK$4.72
- 52-week low
- HK$1.80
- Avg volume (3M)
- —
- Shares outstanding
- 571.33M
- Employees
- 51
- Next earnings
- —
About HighTide Therapeutics, Inc.
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
- ISIN
- KYG4568L1023
- Founded
- 2011
- Listed since
- Dec 22, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Adimmune CorporationTWSE: 4142 | $253.10M | NT$19.20 | +6.67% |
| Lineage Cell Therapeutics, Inc.NYSEAM: LCTX | $251.39M | $0.99 | +6.85% |
| TriSalus Life Sciences, Inc.NasdaqGM: TLSI | $249.99M | $4.06 | -6.02% |
| Zentalis Pharmaceuticals, Inc.NasdaqGM: ZNTL | $249.93M | $2.64 | +4.76% |
| AC Immune SANasdaqGM: ACIU | $248.57M | $2.50 | -8.26% |
| Racura Oncology LtdASX: RAC | $248.34M | AU$1.82 | -5.47% |
| Q32 Bio Inc.NasdaqCM: QTTB | $248.28M | $8.34 | +1.34% |
| Shandong Boan Biotechnology Co., Ltd.SEHK: 6955 | $245.84M | HK$3.10 | +2.31% |
Figures last refreshed Oct 11, 2026.